Could engineered immune cells tame type 1 diabetes?
NCT ID NCT07395050
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This early-phase trial tests whether specially modified immune cells, called CD6-CAR Tregs, can safely control type 1 diabetes. The cells are made from the patient's own blood and designed to stop the immune system from attacking insulin-producing cells. Six adults with stage 3 type 1 diabetes will receive the treatment to check for safety and feasibility.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous anti-CD6 chimeric antigen receptor T regulatory cells (CD6-CAR Tregs)
- What this could lead to
- If successful, this could point toward a way to preserve insulin production in type 1 diabetes, reducing the need for lifelong insulin management.
- What could go wrong
- This is a very early, small pilot study with only 6 participants, so results may not apply broadly. Risks include immune reactions or no benefit to blood sugar control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE 3 TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact